NEW THERAPEUTIC OPTIONS IN IDIOPATHIC PULMONARY FIBROSIS
The Path to Improved Diagnosis and Patient Outcomes
A Series of Live Clinical Topics Grand Rounds and a CME-certified Webcourse.
New Therapeutic Options in Idiopathic Pulmonary Fibrosis: The Path to Improved Diagnosis and Patient Outcomes.
This CME-certified initiative is intended for all healthcare professionals who are part of the multidisciplinary care team for patients with IPF. A series of live CME programs will be presented at selected hospitals throughout the US in 2015 and 2016, and an online CME webcourse will be available in late 2015.
Despite growing prevalence, patients with IPF continue to suffer unacceptable delays in diagnosis and initiation of optimal treatments that can positively impact morbidity and mortality. The management of IPF has changed drastically in recent times, and patients can finally rely on more than supportive care. In October 2014, two new medications received regulatory approval in the US for improvement of symptoms and survival. However, for these agents to be efficacious, major improvements in diagnosis and detection must be made.
New Therapeutic Options in Idiopathic Pulmonary Fibrosis will also review strategies for developing and implementing cross-functional multidisciplinary team initiatives and enhancing communication among health care providers. Via discussions with key opinion leaders, clinicians and their pulmonary units will be better able to perform a critical assessment of current practices and identify barriers to optimal outcomes, following examples from the Pulmonary Fibrosis Foundation (PFF) and the recently established PFF Care Center Network.
These CME-certified activities are intended for pulmonologists, allergists and immunologists, hospitalists, respiratory therapists, rheumatologists, internists, radiologists, pathologists, NPs, PAs, nurses, and other healthcare professionals who are part of the multidisciplinary care team for patients with IPF.
This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
Screen patients presenting with shortness of breath and other risk factors for pulmonary fibrosis and differentiate idiopathic from non-idiopathic forms by applying appropriate diagnostic testing, such as high-resolution CT scanning, to characterize distribution of fibrosis and inflammation
Incorporate current guidelines and new clinical evidence to develop an appropriate management plan for patients with IPF.
Describe strategies to engage patients and facilitate a multidisciplinary approach to the management of IPF and associated comorbidities
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please email email@example.com.
CALENDAR FOR LIVE ACTIVITIES
If you are interested in attending a meeting in your local area, please contact Alexis Haley at 443-909-7907 or firstname.lastname@example.org for the schedule.
Click here for the CME-certified webcourse associated with this program.
LIVE PROGRAM MATERIALS FOR SPEAKERS AND ADMINISTRATORS
Back to Top
I. Administrator Material
II. Speaker Material
Thank you for joining us as an expert speaker for the grand rounds series, New Therapeutic Options in Idiopathic Pulmonary Fibrosis: The Path to Improved Diagnosis and Patient Outcomes.
This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:
- Screening of patients presenting with shortness of breath and other risk factors for pulmonary fibrosis and differentiation of idiopathic from non-idiopathic forms by applying appropriate diagnostic testing, such as high-resolution CT scanning, to characterize distribution of fibrosis and inflammation
- Incorporation of current guidelines and new clinical evidence to develop an appropriate management plan for patients with IPF
- Strategies to engage patients and facilitate a multidisciplinary approach to the management of IPF and associated comorbidities
Transcript of Speaker Orientation Download (PDF)
Audio download of Speaker Orientation
This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PowerPoint)
Steering Committee Biographies
Lisa H. Lancaster, MD
Associate Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Vanderbilt University Medical Center
Lisa H. Lancaster, MD graduated summa cum laude from the University of Georgia in 1989. She graduated from the Medical College of Georgia in 1993 as a member of the Alpha Omega Alpha honor society. She trained in internal medicine at Vanderbilt University from 1996-1999, and completed a pulmonary and critical care fellowship at Vanderbilt University in 1996.
Dr. Lancaster is board-certified in internal medicine, pulmonary medicine, and critical care medicine. Her areas of specialty include idiopathic pulmonary fibrosis, lung transplantation, and sleep medicine.
Keith J. Robinson, MD, MS, FCCP
Associate Clinical Professor,
Nova Southeastern School of Medicine
Oakland Park, FL
Keith J. Robinson, MD, MS, FCCP is board-certified in pulmonary/critical care medicine and practices with Pulmonary Physicians of South Florida, LLC. He is also an Associate Clinical Professor at Nova Southeastern School of Medicine. He is the Medical Director of Fusion Health: Pulmonary Rehabilitation Center in Oakland Park, FL, where he conducts clinical research in COPD.
Dr. Robinson began his career in medicine by receiving his bachelor’s degree in athletic training/exercise science from Ithaca College in New York. After graduation, he worked two years as a Graduate Assistant in the Women’s Athletic Training Department at Florida State University, while working on his Master’s in Exercise Physiology/Motor Behavior. He completed his medical training at Indiana University, his residency in internal medicine at the University of Florida, and his fellowship in pulmonary/critical care medicine at the University of California, San Diego.
He serves as an Associate Team Physician with the Florida Launch and previously with the LA Riptide, both Major League Lacrosse franchises, and provided onsite medical care at the first MLS Cup for Major League Soccer in 1999. Dr. Robinson is an active member of the Clinical Advisory Committee to the COPD Foundation and serves on the COPD advisory boards for Astra Zeneca Pharmaceuticals and Forest Pharmaceuticals.
Laurie D. Snyder, MD, MHS
Assistant Professor of Medicine
Associate Medical Director, Lung Transplant Program
Pulmonary, Allergy, and Critical Care Medicine Division
Duke University Medical Center
Laurie D. Snyder, MD, MHS, is currently a pulmonologist at Duke University Medical Center. She graduated from Duke University Medical School, completed internal medicine training at the University of California, San Francisco and then her pulmonary and critical care fellowship at Duke University. Dr. Snyder joined the pulmonary faculty at Duke in 2006 and has since focused her clinical and research efforts on advanced lung disease and lung transplantation.
Dr. Snyder subsequently received her Master’s in Health Sciences with a focus in clinical research from the Duke University Graduate School in 2012. In addition to her inpatient and outpatient clinical care time, Dr. Snyder is a member of the Duke Clinical Research Institute and specializes in clinical trials and registries of patients with interstitial lung disease.
Timothy P. M. Whelan MD
Medical Director, Lung Transplantation
Associate Professor of Medicine
Medical University of South Carolina
Timothy P. M. Whelan, MD is an Associate Professor of Medicine and the Medical Director for Lung Transplantation at the Medical University of South Carolina. He received his medical doctorate from the State University of New York at Buffalo in 1995. He completed a residency at the University of Colorado and subsequently completed his fellowship training at the University of Washington. He served as Medical Director of the Interstitial Lung Disease Program at the University of Minnesota from 2003-2010 prior to moving to South Carolina.
Dr. Whelan is an active clinical investigator with more than 10 years of experience evaluating novel therapeutics for patients with idiopathic pulmonary fibrosis. He remains actively involved in clinical trials today and has a specific interest in improving outcomes for patients with severely advanced lung disease and for patients following lung transplantation. He is an active educator through his participation with the pulmonary fellowship and Medicine Residency Programs, and is also dedicated to the continuing education of clinicians who have completed their formal education through his involvement with the American College of Physicians, American College of Chest Physicians, and numerous community outreach programs.